OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Raez on State of Lung Cancer Treatment in Light of COVID-19

May 11th 2020

Luis E. Raez, MD, discusses how the COVID-19 pandemic has impacted the treatment of patients with lung cancer.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

May 10th 2020

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Dr. Hughes on Mutational Risk in Oncology

May 9th 2020

Kevin Hughes, MD, discusses mutational risk in oncology.

Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin Lymphoma

May 9th 2020

Christopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Dr. Burke on Research With Tafasitamab in Lymphoma

May 9th 2020

John M. Burke, MD, discusses research with tafasitamab (MOR208) in lymphoma.

Dr. Accordino on Utility of Liquid Biopsies in Breast Cancer

May 9th 2020

Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.

Dr. Braunstein on Quadruplet Therapies in Multiple Myeloma

May 9th 2020

Marc J. Braunstein, MD, PhD, discusses quadruplet therapies in multiple myeloma.

Dr. Herzog on the FDA Approval of Olaparib/Bevacizumab as Frontline Maintenance in Ovarian Cancer

May 8th 2020

Thomas Herzog, MD, discusses the data that led to the FDA approval of the combination of olaparib and bevacizumab for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to first-line platinum-based chemotherapy with bevacizumab and whose cancer is associated with homologous recombination deficiency–positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.

Dr. Hamilton on the Evolution of Treatment in HER2+ Breast Cancer

May 8th 2020

Erika P. Hamilton, MD, discusses the evolution of treatment in HER2-positive breast cancer.

Dr. Higano on the State of Immunotherapy in Prostate Cancer

May 8th 2020

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant Tumors

May 8th 2020

Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.

Dr. Shah on Biomarkers of Response to Immunotherapy in Gastric/GEJ Cancer

May 8th 2020

Manish A. Shah, MD, discusses biomarkers of response to immunotherapy gastric/gastroesophageal cancer.

Dr. Goy on Comparing the Toxicity Profiles of BTK Inhibitors in MCL

May 8th 2020

Andre Goy, MD, MS, compares the toxicity profiles of available BTK inhibitors in mantle cell lymphoma.

Dr. Wang on the Results of the ZUMA-2 Trial in Relapsed/Refractory MCL

May 8th 2020

Michael Wang, MD, discusses the results of the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Shinohara on Pairing SBRT With Immunotherapy in Prostate Cancer

May 8th 2020

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Dr. Monk on the Significance of Bevacizumab in Cervical Cancer

May 8th 2020

Bradley J. Monk, MD, FACS, FACOG, discusses the FDA approval of bevacizumab and other novel agents in cervical cancer.

Dr. Raphael on the Clinical Implications of the CLL14 Trial

May 8th 2020

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Dr. Saba on Unique Set of Challenges Caused By COVID-19 in Head and Neck Cancer

May 7th 2020

Nabil F. Saba, MD, FACP, discusses how the COVID-19 pandemic has impacted treatment in head and neck cancer and the health care system at large.

DNA-PK as an Emerging Target in Prostate Cancer

May 7th 2020

Karen E. Knudsen, PhD, chair and Hilary Koprowski Professor, Department of Cancer Biology, professor of cancer biology, urology, medical oncology, and radiation oncology, and enterprise director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses DNA-dependent protein kinase (DNA-PK) as an emerging target in prostate cancer.